Research for novel diagnostic marker of gynecologic tumors and establishment of rapid and low invasive detection system by super-targeting antibody.

成功地制备了针对妇科肿瘤的靶向抗体，并建立了高灵敏度的新型肿瘤标志物检测体系。首先，我们制备了抗人NCAM2的mAb，表达于激素依赖型前列腺癌和乳腺癌。此外，我们还建立了7个针对卵巢癌的单抗和1个针对乳腺癌的单抗。第二，为了提高对妇科肿瘤的诊断水平，我们建立了检测人sEPCAM、sCD147、sEphA2和sTROP2的新型夹心ELISA法和免疫层析法，具有较高的灵敏度和特异性。第三，我们研究了子宫内膜癌干细胞中主要表达的生物标志物候选。因此，该方法可用于妇科肿瘤的非侵入性、高灵敏度诊断。

We could succeed to generate the target antibody against the gynecologic cancers and to establish a high-sensitive detection system of novel tumor marker. The first, we generated mAb to human NCAM2 expressed on hormone-dependent prostate and breast cancer. In addition, we established seven mAbs against ovarian cancer and one to breast cancer. The second, in attempt to improve diagnosis for gynecologic cancers, we developed new sandwich ELISA and immunochromatography systems detecting human sEpCAM, sCD147, sEphA2 and sTROP2, respectively, with high sensitivity and specificity. The third, we examined the biomarker candidates that were predominantly expressed in cancer stem cells of endometrial cancers. Thus, this approach is feasible for non-invasive and high sensitive diagnosis for gynecologic cancers.